Actelion ups 2016 guidance on back of strong start for Uptravi

April 21, 2016 5:19 AM

30 0

ZURICH, April 21 Swiss biotechnology firm Actelion on Thursday upped its 2016 guidance on the back of a strong start for its new pulmonary arterial hypertension (PAH) medicine Uptravi.

Europe's biggest biotech firm raised its outlook for core operating income to grow at a high single-digit percentage rate from a low single-digit percentage range previously. Actelion reported first-quarter core operating income of 249 million Swiss francs ($256.4 million), up 8 percent year on year...

Also read: Cousins Properties: 1Q Earnings Snapshot

Read more

To category page